治疗子宫内膜异位症新药——elagolix

Elagolix for the treatment of endometriosis:a new drug

Elagolix是艾伯维和Neurovrine Biosciences联合开发的口服短效促性腺激素释放激素受体(GnRH)拮抗剂,其通过与脑垂体中的GnRH受体竞争结合、降低血液循环中的性腺激素水平发挥疗效。2018年7月23日,elagolix获批用于治疗子宫内膜异位,成为美国食品药品监督管理局首个批准用于治疗子宫内膜异位症的新药。另外,其在子宫肌瘤适应证的Ⅲ期临床研究也值得期待。本文就elagolix的基本信息、作用机制和临床试验情况作一概述。

Elagolix is an oral short acting GnRH receptor antagonist developed by AbbVie and Neurovrine Bioscicnces.Elagolix reduces the level of gonadotropin in blood circulation by competitive binding with GnRH receptor.On July 23,2018,elagolix was approved for the treatment of endometriosis,becoming the first FDA approved new drug for the treatment of endometriosis.In addition,the phase Ⅲ clinical study on the indications of uterine leiomyoma is also worth looking forward to.The basic information,mechanism and clinical trials of elagolix were reviewed.